secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001437749-22-025278
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris doses first subject in Phase 1 trial of inhaled CTGF inhibitor PRS-220 for IPF
--------------------------------------------------------------------------------

- First subject dosed in Phase 1 dose-escalation study of PRS-220, an inhaled Anticalin protein targeting CTGF.
- Study evaluating safety, tolerability, and PK in healthy volunteers; results expected in 2023.
- IPF affects over 3 million patients worldwide; median survival 3-5 years from diagnosis.
- PRS-220 is the second inhaled respiratory program Pieris has brought into the clinic.
- CEO Stephen Yoder highlights potential for meaningful improvement in quality of life for IPF patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774922025278/0001437749-22-025278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774922025278/pirs20221031b_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-025278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer